Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.

@article{Guix2008ShortPT,
  title={Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.},
  author={M. Guix and N. M. Granja and I. Meszoely and Theresa B Adkins and Bobbye M. Wieman and Kerek E Frierson and V. Sanchez and M. Sanders and A. Grau and I. Mayer and G. Pestano and Y. Shyr and S. Muthuswamy and B. Calvo and H. Krontiras and I. Krop and M. Kelley and C. Arteaga},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 6},
  pages={
          897-906
        }
}
  • M. Guix, N. M. Granja, +15 authors C. Arteaga
  • Published 2008
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • PURPOSE To administer the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to patients with operable untreated breast cancer during the immediate preoperative period and to measure an antiproliferative and/or a proapoptotic effect in the post-therapy specimen and determine a biomarker profile associated with evidence of erlotinib-mediated cellular activity. PATIENTS AND METHODS Newly diagnosed patients with stages I to IIIA invasive breast cancer were treated with… CONTINUE READING
    97 Citations
    Tyrosine Kinase Inhibitors in Triple Negative Breast Cancer
    • 3
    • PDF
    Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial
    • 9
    A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer
    • 28
    Target-based therapies in breast cancer: current status and future perspectives.
    • 75
    • Highly Influenced
    • PDF
    Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer.
    • M. Green, P. Francis, +7 authors J. Forbes
    • Medicine
    • Annals of oncology : official journal of the European Society for Medical Oncology
    • 2009
    • 47
    • Highly Influenced
    Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
    • 67
    Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.
    • 100

    References

    SHOWING 1-10 OF 34 REFERENCES
    Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
    • A. Tan, X. Yang, +14 authors S. Swain
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2004
    • 173
    Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
    • 498
    • PDF
    Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer.
    • 53
    • PDF
    Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients.
    • M. Dowsett, N. Bundred, +8 authors D. Muchmore
    • Medicine
    • Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
    • 2001
    • 105
    • PDF
    Erlotinib in previously treated non-small-cell lung cancer.
    • 3,704
    • PDF
    Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
    • K. Chung, J. Shia, +11 authors L. Saltz
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2005
    • 1,086